CRBP Corbus Pharmaceuticals Holdings Inc

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving Possible Securities Fraud Violations by Certain Officers and Directors of Corbus Pharmaceuticals Holdings, Inc.

NEW YORK--(BUSINESS WIRE)--

Levi & Korsinsky announces it has commenced an investigation of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) concerning possible violations of federal securities laws.

On March 30, 2017, Corbus Pharmaceuticals announced positive topline data from its Phase 2 study evaluating multiple doses of anabasum for the treatment of cystic fibrosis. While the company qualified the news as “positive,” the shares plummeted. Analysis from various reporters revealed that the safety and tolerability results were the result of the Company drawing most of the attention to an efficacy signal in a high-dose group. To obtain additional information, go to:

http://zlk.9nl.com/corbus-pharmaceuticals-crbp

or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972.

Levi & Korsinsky is a national firm with offices in New York, Connecticut and Washington D.C. The firm’s attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.

EN
07/04/2017

Underlying

CRBPCorbus Pharmaceuticals Holdings Inc

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Corbus Pharmaceuticals Holdings Inc

Free Trial
CRBP Corbus Pharmace...

An unfavourable environment weighs on CORBUS PHARMS.HOLDINGS, which se...

The independent financial analyst theScreener just requalified the general evaluation of CORBUS PHARMS.HOLDINGS (US), active in the Biotechnology industry. As regards its fundamental valuation, the title still shows 1 out of 4 stars and its market behaviour is seen as risky. theScreener believes that the unfavourable environment weighs on the sector and penalises the company, which sees a downgrade to its general evaluation to Negative. As of the analysis date November 30, 2021, the closing pric...

CRBP CORBUS PHARMACEUTICALS HOLDINGS INC
12/01/21 December 1, 2021 1 EN
 PRESS RELEASE
Free
CRBP Corbus Pharmace...

Corbus Pharmaceuticals Reports Second Quarter 2021 Financial Results a...

Corbus Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Corporate Updates Company focused on gaining regulatory clarity for late-stage lenabasum program and advancing programs targeting the endocannabinoid system and integrins into the clinicAugmenting the pipeline through business development continues to be a priorityCash and investments on hand of $114M provides projected runway into first quarter of 2024 Norwood, MA, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), an immunology company...

August 12, 2021 1 EN
 PRESS RELEASE
Free
CRBP Corbus Pharmace...

Corbus Pharmaceuticals Announces Topline Results from DETERMINE Phase ...

Corbus Pharmaceuticals Announces Topline Results from DETERMINE Phase 3 Study of Lenabasum for Treatment of Dermatomyositis Study did not meet primary endpoint of Total Improvement Score (TIS) at Week 28Additional findings included nominally significant improvements in TIS (p = 0.0302) and CDASI (p = 0.0166) depending on the dermatomyositis subtypeLenabasum treatment was safe and well-tolerated in this study Norwood, MA, June 24, 2021 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), an immunology company developing innovative medicin...

June 24, 2021 1 EN
 PRESS RELEASE
Free
CRBP Corbus Pharmace...

Corbus Pharmaceuticals Licenses Two Integrin Targeting mAbs Further Ex...

Corbus Pharmaceuticals Licenses Two Integrin Targeting mAbs Further Expanding Pipeline into Cancer and Fibrotic Diseases Corbus diversifies pipeline with two new mAbs that target integrins that inhibit activation of TGFβ High potency anti-αvβ8 mAb licensed from University of California San Francisco and anti-αvβ6/αvβ8 mAb licensed from Panorama Research Inc. Both mAbs expected to start Phase 1 testing in 2022Capital and resources in place to advance multiple programs into clinical developmentCompany to host conference call and webcast today, Tuesday, June 1, 2021 at 8:30 a.m. ET Norwoo...

June 1, 2021 1 EN
 PRESS RELEASE
Free
CRBP Corbus Pharmace...

Corbus Pharmaceuticals Announces Publication of Two Abstracts at EULAR...

Corbus Pharmaceuticals Announces Publication of Two Abstracts at EULAR 2021 Virtual Congress Norwood, MA, May 25, 2021 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system, today announced the publication of two abstracts at the European League Against Rheumatism (EULAR) 2021 Virtual Congress that will be taking place June 2-5, 2021. Details of the presentations are as follows: Presentation Title: Phase 3 Trial of Lenab...

May 25, 2021 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch